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2ABSTRACT
The copy number of the N-myc oncogene provides a prognostic index for 
neuroblastoma. The mechanism for this is not known, but may be related to 
cellular resistance to radiation or cytotoxic drugs.
Seven human neuroblastoma cell lines were used to investigate the relationship 
between N-myc copy number or expression and sensitivity to ionising radiation and 
cisplatin. N-myc copy number was assessed by Southern blotting and hybridisation 
using the p-Nbl probe. The signal produced from DNA of the cell lines was 
compared with that of human placental DNA which has single copy N-myc (the 
normal copy number for diploid cells). A range of N-myc copy numbers from 1
- 800 was found. Expression levels of N-myc messenger RNA were compared by 
"dot-blotting” and subsequent hybridising to the p-Nbl probe. Radiosensitivity was 
investigated by irradiating multicellular tumour spheroids or cell monolayers using
a 60Co source, (dose range 0.5 - 5 Gy). Survival curves were produced using both
*
colony formation and spheroid regrowth delay as end points. The response to 
radiation was assessed by surviving fraction at 2 Gy (SF2); values ranged from 0.13
- 0.52. Sensitivity to cisplatin was indicated by comparison, of isoeffective 
concentrations (concentration required to produce 1 log cell kill) from survival 
curves produced as above. These concentrations ranged from 7.5 - 13 pM.
Cisplatin studies showed a border-line correlation between N-myc copy number 
(though not expression) and resistance to this drug. If this relationship is causal it 
may explain why treatment fails in those patients with elevated N-myc copy number. 
However, no correlation was found between N-myc copy number or expression and 
sensitivity to radiation. It is possible that N-myc amplification confers resistance to 
some, but not all, treatments used in the therapy of neuroblastoma. Further 
investigations along these lines may lead to the identification of agents which are 
most appropriate for the treatment of neuroblastoma with amplified N-myc gene.
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CHAPTER 1. CANCER RELATED GENES
6
INTRODUCTION
In the early 1980’s, the molecular genetic era of human cancer was ushered in with 
the discovery of "dominantly acting" activated cellular oncogenes (Krontiris & 
Cooper, 1981; Shih et al 1981). Oncogenes are cellular genes which may, in the 
activated form, contribute to the process of malignant change. The first activated 
oncogenes were isolated by transfection of DNA from human tumour cells into 
mouse N IH 3T3 cells, a process that gave rise to cellular changes thought to be 
consistent with neoplastic transformation (see page 7). These activated oncogenes 
were quickly discovered to be homologous to transforming retroviral genes (Der et 
al 1982; Parada et al 1982). This finding, which was predicted on the basis of the 
seminal investigations showing that the avian retroviral src oncogene had evolved 
from the capture of a cellular proto-oncogene, (Stehelin et al 1976) led to the 
identification of a number of putative cellular oncogenes.
The discovery that activated oncogenes could be found in 10 to 30% of human 
cancers led to theories that activation of single or multiple cooperating cellular 
oncogenes was sufficient per se for tumourogenesis to occur. These theories were 
strengthened when it was found that the growing list of oncogene functions included 
growth factors, growth factor receptors, signal transducers, protein kinases and 
transcriptional activators - all of which, when behaving aberrantly, might lead to 
uncontrolled cell proliferation.
Lately another class of cancer related genes has begun to emerge; the so called 
tumour suppressor genes (Stanbridge 1985). Earlier studies had shown that when 
malignant cells were fused with normal cells, the resulting hybrids behaved as 
non-tumourogenic cells. This phenomenon of tumour suppression indicated that 
a gene (or genes) from a normal cell might replace a defective function in a cancer 
cell, thus allowing it to be influenced by normal regulators of cell growth. Such 
genetic elements have been termed tumour suppressor genes.
ONCOGENES
Oncogenes were first described in viruses. In 1911, Rous described a transmissable 
sarcoma in chickens which was later found to be due to a viral oncogene. 
Subsequently a large number of such viruses have been isolated from rodents, cats 
and monkeys and are known to cause tumours in these species. To date RNA 
viruses have not been implicated in the development of human cancers. Once 
oncogenes were recognised in RNA tumour viruses, studies were carried out to 
ascertain the origin of these sequences. cDNA fragments of oncogene regions 
from the Rous Sarcoma virus were isolated and used to probe DNA from various 
tissues of the chicken. As a result of these investigations, sequences homologous 
to oncogenic regions of the virus were found to be present in the genomic DNA of 
virus-free chickens. Further similar studies revealed DNA sequences homologous 
to viral oncogenes in yeast, mice and humans. These normal cellular sequences 
have been referred to as proto-oncogenes (Bishop 1983; Varmus 1984). An 
oncogene carried by a virus is termed v-o«c; the proto-oncogene is called cone. 
Investigations aimed at determining whether oncogenes firstly arose in viruses or 
cells of higher organisms led to the conclusion that cellular proto-oncogenes most 
likely developed first. Proto-oncogenes have both exons and introns, while v-oncs 
possess only the former. Therefore, it seems more likely that the viruses, by 
infecting host cells, picked up the m-RNA of c-ones (Minden 1987).
TRANSFORMATION ASSAYS
A test of whether a presumed carcinogen - chemical, virus or gene - is in fact a 
genuine carcinogen is the ability to transform cells or produce tumours in animals. 
The mouse fibroblast line NIH 3T3, developed by Green et al in the early 60’s, is 
a powerful tool in transfection studies. One of the main differences between 
non-transformed cells and those which have been transformed is in their growth 
characteristics. Primary cultures of the former grow to a particular density and stop 
and will not resume growth until diluted. This phenomenon is known as "contact 
inhibition". Transformed cells grow in a non-ordered way and tend to pile up; i.e.
8they appear to have lost contact inhibition. It has been found that DNA isolated 
from cancer cells, when taken up by 3T3 cells, leads to the transformed phenotype. 
The most advanced assay for in vivo transformation studies currently available 
involves introducing oncogenes into the germ lines of mice or other species. These 
so called transgenic animals are then observed for the development of tumours 
(Burck et al 1988).
PROTO-ONCOGENES
Proto-oncogenes are normal cellular genes which are thought to be involved in 
control of proliferation or differentiation and which, when activated, may contribute 
to tumourogenesis. They can be activated by a number of mechanisms including 
point mutation, amplification and translocation. There are now known to be about 
forty or so cellular proto-oncogenes.
In order for non malignant cells to enter a proliferative state they require an 
external signal which is received by a membrane receptor and is transmitted via 
the cytoplasm to the nucleus (Minden 1987). Proto-oncogenes have been found 
which function at each step of the signal transduction process. For example, the 
erb-B proto-oncogene appears to be homologous to the gene encoding Epidermal 
Growth Factor. The products of the src, abl, and ras proto-oncogenes act at the 
level of secondary messengers on the cytoplasm whereas the myc family of 
proto-oncogenes encode nuclear proteins.
ACTIVATION 
Point Mutation
A point mutation in a gene is the substitution of one nucleotide base for another. 
This in turn may result in a single amino acid alteration in the resulting protein, 
sometimes with dire consequences. For example, in the activated YL-ras gene 
associated with bladder cancer, a single base substitution in the 12th codon causes
the substitution of valine for glycine giving rise to a different protein product (Tabin 
et al 1982; Reddy et al 1982). This altered product has been implicated in the 
initiation of tumourogenesis, and has been found in a bladder tumour cell line. 
However, activated H-ray is only found in a proportion of patients with bladder 
cancer and the significance of this finding to the majority of patients is unknown 
(Thomas and Waxman 1989). Mutations involving the family of ras genes are 
associated with a number of neoplasms including human leukaemias and colon 
carcinomas.
Translocations
These occur frequently in some types of tumours and therefore they may play a role 
in the development of neoplasia. The best known example occurs in chronic 
myeloid leukaemia where there is a reciprocal translocation between chromosome 
9 and chromosome 22 giving rise to a novel gene product and the possible onset of 
tumour development (Rowley 1984). In 1981 Klein proposed that chromosome 
breaks might give rise to activation of oncogenes situated proximal to break points 
(Klein 1981). Recently several genes situated at the sites of common translocations 
have been identified and indeed many of these have turned out to be known 
oncogenes (Minden 1987).
Amplification
Multiple copies of proto-oncogenes are often found in tumour cells; for example 
c-myc amplification in acute promyelocytic leukaemia and N-myc amplification in 
neuroblastoma cells. Amplifications of H-ray, N-ray and K-ras have been reported 
in various tumours (Minden 1987). Amplification of N-myc in neuroblastoma and 
the erb-2/neu proto-oncogenes in human breast cancer have been correlated with 
advanced stage disease and a poor prognosis (Burck et al 1988). However, the role 
of these amplified oncogenes in the development of tumours is not yet known. It 
is possible that amplified oncogenes maintain the aggressiveness of disease rather 
than initiate tumourogenesis.
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TUM OUR SUPPRESSOR GENES
Certain experimental findings suggest that cancer is a recessive disease at the 
cellular level. For example, experiments have shown that the malignant phenotype 
can be suppressed by hybridisation of normal cells with tumour cells (Burck et al
1988). In recent years we have witnessed the discovery of a class of cancer-related 
genes which unlike cellular oncogenes act not to promote malignant change, but to 
suppress it. Accordingly, these tumour suppressor genes or anti-oncogenes are 
manifest not when they are activated (as are cellular oncogenes) but rather when 
they are absent or inactivated. Examples of these include the retinoblastoma 
susceptibility gene (Rb) on chromosome 13 and the deletion on chromosome 11 
associated with Wilms’ tumour. Both these types of tumour require the loss of two 
alleles for onset of tumourogenesis, and in the case of retinoblastoma the loss of 
the first allele is often inherited. Deletion of the short arm of chromosome 1 is the 
most consistent cytogenetic abnormality in primary neuroblastomas. This will be 
described in greater detail later. Some familial cases of neuroblastoma have been 
documented (Hayes and Smith 1989; Brodeur and Fong 1989). Identification and 
cloning of this putative suppressor gene on chromosome 1 may lead to pre-natal 
diagnosis in affected individuals. The importance of these tumour suppressor genes 
in the development of neoplasms is beginning to emerge and it may eventually be 
possible to restore the lost gene as a means of cancer therapy. It is worth 
mentioning the p53 gene at this stage which seems to function both as a 
proto-oncogene and a tumour suppressor gene depending on the type of mutation 
it has undergone. The p53 gene is found in normal cells in all tissues. High 
intracellular levels of its mutant product (a nucleophosphoprotein) is associated 
with various tumours. In fact, about half the common cancers contain mutations 
of the p53 gene, located on the long arm of chromosome 17, and this gene plays a 
central role in cellular growth regulation (Burck et al 1988). Examples of these 
cancers include colon, lung, oesophagus, breast, liver, brain and haemopoietic 
tissues (Hollstein et al 1991). Analyses of these mutations may provide clues to the 
cause of this variey of tumours and to the function of specific regions of the p53 
gene (Hollstein et al 1991).
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CHAPTER 2. NEUROBLASTOMA
INTRODUCTION
Neuroblastoma is a tumour of post-ganglionic sympathetic neurones and is 
neuro-ectodermal in origin. It is the most common extra-cranial solid tumour in 
children and comprises 25-50% of all malignant tumours in neonates. It occurs at 
a rate of 1 per 10,000 live births with the malerfemale ratio 1.2:1 and the white to 
black ratio 3:2. On presentation, 45% of neuroblastoma patients already have 
distant skeletal metastases (O’Brien et al 1989). Of all patients with neuroblastoma 
50% are less than two years old and 75% are less than four years old. It is 
extremely rare for any patient to exceed fourteen years of age (Voute 1988). 
Genetic pre-disposition to the disease is a possibility the presence of neuroblastoma 
in siblings and identical twins has been well documented (Hayes and Smith 1989).
Primary tumours can arise in numerous sites within the peripheral nervous system 
from the base of the skull to locations deep in the pelvis and adrenals. 70% of 
cases originate in the retroperitoneal region and 30% in the adrenal glands. The 
site of the primary tumour is an important prognostic factor; neuroblastomas arising 
in the cervical, thoracic and pelvic regions are more favourable than those of 
adrenal origin (Voute et al 1986). Liver, bone and lymph nodes are common 
metastatic sites, whereas brain, spinal cord, heart and lungs are rarely affected 
(Voute et al 1986: Voute 1988). Biological markers for neuroblastoma include 
urinary excretion of Vanillylmandelic and Homovanillic acids and the ratio of one 
to the other predicts outcome: the higher the value, the better the outcome (Hayes 
and Smith 1989). Some patients also excrete increased levels of cystathionine and 
homocysteine, both of these amino acids occuring in nervous tissue and liver (Voute
1988).
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STAGING
The current system is the International Staging System for Neuroblastoma (Brodeur 
et al 1988a). Table 1 shows this system and the older Paediatric Oncology Group 
(POG) system of staging for comparison (Kretschmar 1991)
International Staging System for 
Neuroblastoma
Paediatric Oncology Group
Stage 1: Localised tumour confined to the 
area of origin; complete gross excision, with 
or without microscopic residual disease; 
identifiable ipsilateral and contralateral lymph 
nodes negative microscopically.
Stage 2A: Unilateral tumour with incomplete 
gross excision; identifiable ipsilateral and 
contralateral lymph nodes negative 
microscopically.
Stage 2B: Unilateral tumour with complete 
or incomplete gross excision; with positive 
ipsilateral regional lymph nodes; identifiable 
contralateral lymph nodes negative 
microscopically.
Stage 3: Tumour infiltrating across the 
midline with or without regional lymph node 
involvement; or unilateral tumour with 
contralateral regional lymph node 
involvement; or, midline tumour with bilateral 
regional lymph node involvement.
Stage 4: Dissemination of tumour to distant 
lymph nodes, bone marrow, liver, and/or 
other organs (except as defined in stage 4S).
Stage 4S: Localised primary tumour as 
defined for stage 1 or 2 with dissemination 
limited to liver, skin, and/or bone marrow.
Stage A: Complete gross resection of 
primary tumour, with or without microscopic 
residual. Intracavitary lymph nodes, not 
adherent to but removed with the primary, 
must be histologically free of tumour. Nodes 
adherent to or within the tumour resection 
may be positive for tumour without restaging 
patient to Stage C. If primary is in abdomen 
or pelvis, liver must be histologically free of 
tumour.
Stage B: Grossly unresected primary tumour. 
Nodes and liver as in Stage A.
' J
Stage C: Complete or incomplete resection 
of. primary. Intracavitary nodes that are not 
adherent to the primary are histologically 
positive for tumour. Liver as in Stage A.
Stage D: Any dissemination of disease 
beyond intracavitary nodes, that is, 
extracavitary nodes, liver, skin, bone marrow, 
or bone.
Table 1 Comparison of the new International Staging System for 
Neuroblastoma with the older POG System.
CURRENT TREATMENT AND SURVIVAL
Although some patients, especially infants, seem to be curable with little or no 
therapy, conventional treatment has little effect on the long term outcome notably 
for older children with disseminated disease (Brodeur and Fong 1989). Since the 
majority of patients present with stage 4 and are over 1 year of age, current therapy 
is far from satisfactory. Spontaneous regression occurs in about 1% of children with 
neuroblastoma, largely among infants with stage 4S (Hayes and Smith 1989). By 
virtue of its neural crest origin, neuroblastoma has the potential to mature into 
either ganglioneuroblastomas or pheochromocytomas (Voute 1988). Survival 
depends on age (the younger the patient the better the outcome) and, as mentioned 
previously, the site of the primary. Survival also depends on the stage at the time 
of presentation and a study of 100 children showed an 80% two year survival for 
stage 1 disease compared to 7% for stage 4 (Voute et al 1986). Figure 1 shows 
survival of children older than 1 year of age with POG staged disease (Hayes and 
Smith 1989). No historical date has been collected for the International Staging 
System. Current treatment for neuroblastoma is multimodal, typically involving 
surgery, chemotherapy and possibly radiotherapy.
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Figure 1. Survival of children older than 1 year of age with POG stage disease 
treated at St. Judes Childrens Research Hospital, 1974-1984.
CHEM OTHERAPY
Although chemotherapy has not altered long term survival it has been shown to 
induce complete or partial response in some patients (O’Brien et al 1989). 
Examples include cis-Diamminedichloroplatinum (11) (cisplatin) with a 46% 
complete or partial response rate, and cyclophosphamide, 59% (Hayes and Smith
1989). Currently these agents are not used singly but in combination with others 
(see page 27 also).
RADIOTHERAPY
Radiotherapy mostly improves local control and may provide palliation in painful 
boney metastases and spinal cord compression (O’Brien et al 1989). Therapeutic 
doses range from 15-35 Gy depending on age and the site being irradiated. Total 
body irradiation is used in conjunction with marrow transplantation in some 
programmes (Hayes and Smith 1989).
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CHAPTER 3. MOLECULAR GENETICS OF NEUROBLASTOMA
INTRODUCTION
There are two genetic events known to be associated with neuroblastomas. These 
are the deletion of the distal portion of the short arm of chromosome one and 
N-myc amplification. The two events are thought to be related and loss of 
heterozygosity of chromosome lp  (LOH) may precede amplification (Brodeur
1990).
N-myc AMPLIFICATION
A specific oncogene (N-myc) has been found to be amplified in certain 
neuroblastoma cell lines and tumours (Schwab et al 1983; Kohl et al 1983). 
Amplification or increased expression of N-myc would so far appear to be restricted 
to a subset of tumours of neural origin, including small cell lung cancer and 
retinoblastoma (Lee et al 1984), although an exception to this is rhabdomyosarcoma 
which sometimes contains amplified copies of the N-myc gene (Dias et al 1990). 
The N-myc gene has been sequenced and was found to be related to but only 
partially homologous to v-myc and c-myc (Schwab et al 1983; Kohl et al 1983).
One of the first studies of N-myc amplification in a number of primary untreated 
tumours indicated that 38% of these had gene amplification and that this 
phenomenon correlated with poor prognosis. Those patients with stage 3 and 4 
disease were found to have N-myc amplification far more frequently than stage 1, 
2A, 2B or 4S (Brodeur et al 1984). In a later study 2/16 patients described as stage 
2A, 2B had amplification and rapid tumour progression whereas only 1 of the 
remaining patients without amplification progressed (Seeger et al 1985; Brodeur et 
al 1986).
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The studies were later extended to over 600 patients and the results confirmed 
earlier findings: 5-10% of patients with 1, 2A, 2B and 4S stage disease had 
amplification and poor outcome similar to advanced stage disease and 30% of 
children with advanced stage neuroblastoma had amplification and poor prognosis 
(Brodeur et al 1988b; Brodeur 1990). These observations still seem to be generally 
true as seen from investigations in other laboratories (Tsuda et al 1988; Nakagawara 
et al 1987; Bartram and Bertold 1987; Combaret et al 1989; Hiyama et al 1991; 
Looker al 1991; McQuaid and O-Meara 1990). Therefore N-myc amplification may 
be a valuable prognostic indicator.
CHROMOSOME lp DELETION AND PLOIDY
Flow cytometry studies on neuroblastoma patients have shown that V3 of tumours 
have a near diploid karyotype, with the remaining 2/ 3 showing hyperdiploidy 
(Delattre et al 1991; Look et al 1991). A recent study showed that for children less 
than 12 months old, hyperdiploidy correlated with long term disease free survival 
(>90% ), whereas diploidy correlated with early treatment failure. In the group 
aged from 12 to 24 months hyperdiploidy correlated with 50% long term disease 
free survival and diploidy again correlated with early treatment failure (Look et al
1991). Overall, in children under 2 years old with disseminated disease, tumour 
cell ploidy and N-myc copy number can provide complementary prognostic 
information. Deletion of the distal portion of chromosome lp  is the most 
characteristic cytogenetic abnormality found in neuroblastomas, and it may be 
associated with the loss of a putative tumour suppressor gene (Brodeur and Fong
1989). This may involve inactivation of two alleles as in the case of retinoblastoma 
and Wilms’ tumours (Delattre et al 1991). A large deletion involving the loss of 
appreciable material on chromosome lp  is found in about 30% of tumours and 
correlates strongly with N-myc amplification (Fong et al 1989). Deletions involving 
chromosome 1 are not restricted to neuroblastomas but are found in a variety of 
tumours including breast, melanoma and colon cancer (Brodeur 1990; Delattre et 
al 1991).
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GENETIC PREDISPOSITION
The possibility of an inherited susceptibility to neuroblastoma is supported by the 
existence of familial clusters which represent a very small incidence ( < 1% ) of all 
neuroblastomas (Brodeur and Fong 1989; Delattre et al 1991). The tendency 
towards developing neuroblastoma could be inherited as in retinoblastoma and 
Wilms’ tumour. The localisation of the gene whose constitutional mutation gives 
rise to germline transmission has yet to be pin-pointed. Neuroblastoma differs from 
retinoblastoma and Wilms’ tumour in that there is no consistent constitutional 
chromosome abnormality or specific congenital syndrome associated with it 
(Brodeur and Fong 1989; Delattre et al 1991). A possible site for the predisposition 
gene may well be that of the putative tumour suppressor gene as observed in other 
tumours.
It has lately emerged that there are two distinct groups of neuroblastoma; type 1, 
consisting of those tumours which show a near-diploid karyotype with N-myc 
amplification and lp deletion and type 2 which are hyperdiploid with no evidence 
of either of the above. Type 1 disease carries a poor prognosis, whereas those 
patients with type 2 disease have a favourable outcome (Brodeur and Fong 1989; 
Delattre et al 1991; Dominici et al 1989). Both types may share as a common 
mechanism for tumourogenesis the deletion of a tumour suppressor gene on 
chromosome 1, but would differ by the size of the lp  deletion involved in the 
second hit (Delattre et al 1991).
In summary, DNA content, N-myc amplification and lp  deletion are now regarded 
as strong prognostic indicators. These genetic markers could be used to predict the 
aggressiveness of the disease and to decide whether to use more intense therapy. 
Ascertaining the sequence and position of the neuroblastoma predisposition gene 
could assist in pre-natal diagnosis by identifying those individuals most at risk of 
developing neuroblastoma.
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POSSIBLE ROLE OF N-myc
Despite the relationship between elevated N-myc copy number and tumour 
aggressiveness, it is by no means clear what role N-myc amplification plays in this 
phenomenon. Furthermore, while approximately 30% of children with 
neuroblastoma have N-myc amplification in their tumours, there are still about 50% 
of the remaining children with single copy who do not survive (Brodeur and Fong
1989). Evidence of other amplified oncogenes in over 100 neuroblastomas was 
sought but none was found (Brodeur and Fong 1989). There is no consistent 
evidence implicating activation of an oncogene other than N-myc with the poor 
outcome seen in a subset of patients lacking N-myc amplification. Clearly N-myc 
amplification alone cannot be responsible for malignant transformation in this 
tumour.
In order to test the ability of an oncogene to transform cells, transfection studies 
can be carried out on mouse or rat embryo fibroblasts. Experimental models such 
as these have shown the contribution of N-myc overexpression in tumourogenesis. 
Introduction of an N-myc expression vector immortalises primary rat embryo 
fibroblasts or neural precursor cells (Delattre et al 1991). N-myc can co-operate 
with an activated ras gene to induce transformation in rat embryo cells (Schwab et 
al 1985). Transgenic mice bearing the N-myc oncogene deregulated by juxtaposition 
of the immunoglobulin heavy chain enhancer may spontaneously develop B 
lymphoid tumours (Rosenbaum et al 1989). Therefore, clearly the N-myc oncogene 
can contribute to carcinogenesis.
A study of N-myc copy number in multiple simultaneous tumour samples and 
consecutive samples from individual patients showed that N-myc copy number did 
not vary between different sections of a single tumour or during treatment from the 
same patient over a period of time (Brodeur et al 1987). So far no cases of 
neuroblastoma with one copy at the time of diagnosis have been known to go on
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to develop multiple copies (Brodeur and Fong 1989). The results suggest that 
tumours which develop N-myc amplification generally do so by the time of diagnosis 
and that this feature is an inherent property of a sub-set of aggressive 
neuroblastomas.
N-myc GENE PRODUCT
Nuclear proteins encoded by the myc family of genes appear to function in normal 
cells in proliferative control and in maintaining the self-renewal capacity of the cell 
(Westin et al 1982; Filmus and Buick 1985). In normal cells the expression of myc 
and other proto-oncogenes encoding nuclear proteins (e.g. fos and myb) is tightly 
controlled, but the expression of these in transformed cells is not so highly 
regulated (Hann and Eisenman 1984).
The c-myc gene is expressed in a variety of normal cells and encodes a nuclear 
protein that binds to DNA; therefore it may mediate in the pathway of mitotic 
signals. N-myc is only expressed in embryos and at a lower level in adult brain and 
testes (Stanton et al 1986). The N-myc and c-myc genes have a similar intron/exon 
structure and their protein products share regions of significant homology (Kohl et 
al 1986). Stanton et al (1986) suggested a possible function for the N-myc gene 
product. The ability of the c-myc product to bind to DNA may reside in the 
carboxy terminal of the protein, the region most conserved between c-myc and 
N-myc gene products. Thus it is possible that the protein encoded by N-myc may 
also bind to DNA and suggests that members of the myc family, whilst related, may 
be uniquely regulated.
N-myc EXPRESSION
N-myc is expressed at elevated levels in a limited set of neoplasms; those of 
neuro-ectodermal origin including neuroblastoma, retinoblastoma, small cell lung 
cancer and Wilms’ tumour (Nisen et al 1988; Kohl et al 1984). A study by Nisen
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et al (1988) on a number of neuroblastoma patients indicated that there was a 
rough correlation between N-myc RNA expression and degree of amplification of 
N-myc, but that elevated expression was not confined to tumours with amplified 
N-myc. This observation has been borne out by other investigators (Kohl et al 
1984; Bartram and Bertold 1987). A substantial number of tumours lacking N-myc 
amplification overexpress the N-myc gene but this increased level of expression does 
not correlate strongly with a poor outcome (Seeger et al 1988; Nisen et al 1988). 
Increased RNA expression is a more general phenomenon found in individual 
specimens at all clinical stages in neuroblastoma without any obvious correlation 
to disease severity or outcome. It is possible that N-myc expression is a marker of 
specific stage in the neuroblastoma cell lineage at which neuroblastomas are 
blocked; i.e. increased N-myc expression correlates with poorly differentiated cells. 
In situ hybridisation studies on tumour sections show stronger signals largely in 
poorly differentiated tumour cells (Schwab 1984; Cohen et al 1988). Neuroblasts 
can be induced to differentiate by, for example, retinoic acid - an analogue of 
Vitamin A. Thiele et al showed a decrease in N-myc expression after treating 
neuroblastoma cell lines with the above. This decrease preceded differentiation 
identified by morphological changes in the form of outgrowth from neuroblasts 
(Thiele et al 1985). Southern blots of tumour cell line DNA post treatment showed 
no reduction in N-myc copy number - therefore the decreased expression was not 
due to this. Retinoic acid may therefore have some therapeutic value in the 
treatment of neuroblastoma by inducing differentiation to a benign 
ganglioneurob lastoma.
Christiansen et al (1990) found an inverse relationship between N-myc RNA 
expression and expression of the gene for Nerve Growth Factor Receptor (NGF-r). 
This inverse relation could help in establishing markers for prognosis. Nerve 
growth factors are polypeptides involved in the control of differentiation of neural 
cells. Christiansen et al found two groups of tumours. Those undifferentiated types
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with elevated N-myc expression and missing NGF-r transcripts which correlated with 
early neuronal development and poor prognosis; and those more highly 
differentiated tumours with diminished N-myc expression and elevated NGF-r 
expression which had a better outcome (Christiansen et al 1990).
The restricted pattern of N-myc expression indicates that expression of this gene 
may be a property of the normal cells from which these tumours derive and may 
not necessarily relate to the neoplastic state (Kohl et al 1984). The N-myc gene is 
expressed in foetal and neonatal tissues and neuroblastoma tumours. The 
expression is elevated during foetal development and falls off dramatically during 
later development (Larcher et al 1991). Increased N-myc expression is found in 
human foetal brain and developing tissue. It is also observed at elevated levels in 
whole mouse embryos between 7.5 and 11.5 days of growth, decreasing thereafter 
(Mugrauer et al 1988). Therefore, it would appear that the N-myc gene plays an 
important role in normal neuronal development.
STRUCTURE AND SIZE OF AMPLFIED N-myc.
Double minute chromosomes (DM’s) and homogeneously staining regions (HSR’s) 
are cytogenetic manifestations of gene amplification. Both phenomena appear 
often in tumour cells, especially neuroblastoma. Double minutes were first 
recognised in neuroblastoma (Cox et al 1965) and homogeneously staining regions 
were described in association with both neuroblastoma and drug resistant Chinese 
hamster cells (Biedler et al 1976). A small percentage of primary neuroblastoma 
tumours and roughly 50% of cell lines have their DNA amplified as HSR’s linearly 
integrated into a chromomsome. It has not yet been established why HSR’s are the 
more common form of amplified DNA in cell lines, although it is probable that 
DM’s are lost more readily from the cell. Amplified N-myc was mapped to the 
HSR’s in cell lines of neuroblastoma (Kohl et al 1983) and in 1984, Schwab et al 
mapped the constitutional site of the N-myc oncogene to the short arm of 
chromosome 2 (Schwab et al 1984). Kohl et al studied five HSR-containing 
neuroblastomas with amplified N-myc and observed that the site of the HSR, in 
each case varied but was never on chromosome 2.
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Brodeur and Seeger (1986) suggest that from current evidence it would appear that 
a large region of chromosome 2, which includes the N-myc locus, becomes amplified 
initially as extrachromosomal DM’s. This is supported by the fact that one rarely 
sees the HSR at the site of the single gene copy. Shiloh et al (1985) analyzed the 
organisation of sequences in the HSR on chromosome 1 of the IMR-32 
neuroblastoma cell line. Probes obtained from the HSR mapped to at least three 
different sites on the short arm of chromosome 2. These were millions of base 
pairs apart. This suggests a complex mechanism in which sequences which are 
usually distant are spliced together and amplified in the cell line. Brodeur and 
Seeger suggest that the entire region of amplified sequences within the HSR 
probably exists as a linear array integrated into a chromosome. Furthermore N-myc 
is probably at the core of the amplified domain in human neuroblastomas but little 
else is known about the limits of the core or genes expressed within it. Further 
analysis may show other important expressed genes and analysis of the ends may 
reveal more about the mechanisms of gene amplification. Schwab (1991) states that 
the major proportion of amplified DNA in neuroblastoma is arranged as head to 
tail tandem repeats.
Various attempts have been made to estimate the size of the HSR containing the 
amplified N-myc oncogene and the amplified units therein. Bahr et al (1983) 
estimated the size of the HSR in a neuroblastoma cell line to be about 8% of the 
human haploid genome which is also supported by Brodeur et al (1988c) who 
observed that an FISR may be as large as chromosome 1,. so there is potential for 
a very large number of copies of N-myc. Since, for example, 30 copies of N-myc 
(which is roughly 10 kbp long) would account for only 0.1% of an HSR then 99.9% 
of the HSR is something else. This suggests that the presence of amplified N-myc 
may only be a marker and that other amplified genes within the HSR may be 
important.
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INTRODUCTION
Neuroblastoma is usually chemoresponsive and, in some instances, curable. The 
main reason for failure of treatment is the rapid dissemination of this disease (Pizzo 
et al 1989). The most common agents used are cyclophosphamide, cisplatin, 
vincristine and melphalan (Pizzo et al 1989). These are employed in combination; 
for example the OPEC regime uses vincristine (oncovine), cisplatin (jrt), VP16 
(etoposide) and cyclophosphamide. Although chemotherapy can result in complete 
responses, recurrence is common in those patients over one year old. The major 
barrier to the success of chemotherapy in neuroblastoma is the development of drug 
resistance in the tumour cells. This will be described in greater detail in the section 
on drug resistance (page 28).
CISPLATIN
Cisplatin is one of the most effective anti-tumour agents used in the treatment of 
advanced neuroblastoma in children (Sue et al 1988). Its mechanism of action is 
similar to that of classical alkylating agents (e.g. cyclophosphamide and melphalan). 
Cisplatin forms covalent bonds with DNA, thus inhibiting its replication and/or 
transcription. Cisplatin may have increased activity for some cells in G1 phase, with 
little or no specificity for others. Most drugs have a greater toxicity toward rapidly 
proliferating cells, but there are some exceptions including cisplatin. Studies of the 
kinetics of the formation of cross-links between cisplatin and DNA indicates that 
these DNA-protein cross-links remain for several hours after removal of the drug 
and then repair occurs (Caiman et al 1980; Tannock 1988).
D RU G  RESISTANCE
Chemotherapy can fail for a number of reasons including the proliferative state of 
the target cells, vascular access and poor penetration of drug into the tumour. 
However, one of the main barriers to successful treatment is the emergence of a 
drug-resistant sub-population among the tumour cells.
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Gene amplification in tumour cells is often found associated with drug resistance. 
One of the best characterised examples of amplification is that of the gene encoding 
dihydrofolate reductase (DHFR), the target enzyme of methotrexate (Schimke 
1982). Those tumour cells containing amplified DHFR genes express the 
chemo-resistant phenotype. Another example of gene amplification and drug 
resistance occurs in the multidrug-resistance phenomenon. It has been observed 
that tumour cells selected for resistance to one of a group of drugs may exhibit 
cross resistance to other members of that group. Examples of drugs which 
participate in multidrug-resistance are vincristine, adriamycin, etoposide and 
daunomycin (cisplatin does not participate). When membrane proteins from 
multidrug-resistant cells are analysed they are found to contain a glycoprotein 
termed P-glycoprotein. Multidrug-resistant cells have decreased uptake and 
increased efflux of drugs to which they are resistant and this alteration in 
membrane transport has recently been correlated with the expression of 
P-glycoprotein. The amplification of the mdr-1 gene causes over-production of the 
above, which seems to act as an "efflux pump" (Tannock 1988). One study of 35 
neuroblastoma samples showed an inverse correlation between expression of the 
mdr-1 and N-myc genes (Nakagawara et al 1990). An investigation by Bourhis et 
al (1989) indicated a correlation between mdr-1 expression levels and previous 
chemotherapy in 41 neuroblastoma tumour samples. Although cisplatin does not 
participate in multidrug-resistance its effectiveness as a cytotoxic agent is often 
reduced by the development of drug-resistant tumour cells. Resistance may arise 
in vivo by repeated exposure to cisplatin. Studies of the mechanism of cisplatin 
resistance have been conducted in a variety of human and rat tumour cell lines 
(Sekiya et al 1989; Andrews et al 1989). Exposure of cells to cisplatin does not lead 
to cross resistance to other agents (apart from cisplatin analogues). This is in 
contrast to the multidrug-resistance phenomenon (Gibson 1989). Therefore uptake 
of cisplatin into cells and development of resistance may involve different 
mechanisms from those found in drugs such as adriamycin and vincristine which 
participate in the multidrug-resistance phenomenon. The concentration of cisplatin
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in resistant cells is decreased by diminished uptake rather than by increased efflux 
as observed in the case of drugs involved in the multidrug phenomenon (Tannock
1988). A conflict exists regarding the exact mechanism of cisplatin membrane 
transport. The uptake of cisplatin may involve more than passive diffusion and it 
has been suggested that membrane transport mechanisms may be involved and that 
one target for cisplatin toxicity may be the plasma membrane (Andrews et al 1989).
MECHANISMS OF RESISTANCE TO CISPLATIN
The biochemical changes responsible for the acquisition of resistance to cisplatin 
are not fully understood. A variety of studies have shown a correlation between 
resistance and increased intra-cellular levels of glutathione (Canon et al 1990). 
Moreover, an increase in DNA repair has been reported for some resistant lines 
coupled with a decrease in uptake of cisplatin (Sekiya et al 1989). Andrews et al 
(1989) observed, from their studies on a resistant subline of human colon 
carcinoma, that mechanisms of resistance are complex, multi-factorial responses. 
Treatm ent with aphidicolin, an inhibitor of DNA polymerase a leads to a decrease 
in DNA repair capacity and partially restores the sensitivity of cisplatin resistant 
lines. However, its potential clinical use is limited by the fact that it is unlikely to 
be tumour specific (Canon et al 1990). Overall, the data suggest that ap increase 
in DNA repair capacity contributes to the cisplatin resistant phenotype. Cisplatin 
analogues to which tumour cells are not cross-resistant may be an important step 
in overcoming the problems of treating neuroblastoma tumours that develop 
resistance to this class of drugs.
The observation that malignant cells often become resistant to drug therapy, while 
normal cells rarely do, suggests that certain molecular processes involved in 
tumourogenesis (e.g. oncogene activation) might also play a role in drug resistance. 
A study into the possible role of oncogenes in the development of resistance to 
chemotherapy was carried out on mouse NIH 3T3 cells transformed with missense
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mutation activated ras genes (Sklar 1988a). A substantial increase in resistance to 
cisplatin was demonstrated. If these findings extend to human tumours, it may help 
to explain the role of activated oncogenes (e.g amplified N-myc in neuroblastoma) 
in the development of drug resistance (Sklar 1988a). In another study Sklar found 
a correlation between cisplatin resistance and levels of c-myc expression in murine 
erythrolukaemia cells (Sklar 1991). He postulated that c-myc levels may influence 
treatment success in some tumours by perhaps enhancing repair of DNA damage 
caused by cross linking agents such as the platinum analogues. These studies into 
the possible role of activated oncogenes in the development of drug resistance are 
given further support with an investigation by Kerr et al. This study showed that 
a mink lung epithelial cell line became significantly more resistant to doxorubicin 
and vincristine than the parent line following transfection with activated H-ray-1 
(Kerr et al 1991).
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INTRODUCTION
Neuroblastoma is clinically radiosensitive but is still often fatal due to its early 
pattern of dissemination via both lymph nodes and blood. The stage of the 
tumour, age at diagnosis, histology and site of tumour are all important prognostic 
variables (D ’angio 1987). In general, the younger the patient the better the 
prognosis, stage for stage. The clinical response of neuroblastoma has been well 
documented, and a high probability of local tumour control can be attained by using 
doses less than 30 Gy typically given as fractions of 2 Gy on a daily basis (Dobbs 
et al 1992). The use of total body irradiation, aggressive chemotherapy and 
autologous bone marrow rescue is a possible treatment regime for those patients 
with metastatic disease.
RADIOBIOLOGY
Human tumours show a widely varying clinical response to radiation. For example, 
seminoma is a highly radioresponsive neoplasm, whereas melanoma is relatively 
refractory. The biological basis for these differences remains unexplained (Deacon 
et al 1985). Current ideas on the radiobiology of human tumours may be divided 
into three categories:-
(1) Cells experience different amounts of damage for the same radiation dose 
depending on how their DNA is packaged.
(2) Cells suffer the same damage but some are good at repair while others are 
less efficient.
(3) Cells suffer the same damage, are equally efficient at repairing, but differ in 
their tolerance to ionising radiation (Powell and McMillan 1990).
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Most of the early work on radiobiology was performed on mouse tumours; however 
the development of in vitro cloning techniques has made human tumour 
radiobiology possible to study (Courtney and Mills 1978; Hamburger and Salmon 
1977). Survival curves can now be produced for mammalian cells irradiated in vitro. 
Cells are irradiated and subsequently plated out to produce colonies. After about 
ten days macroscopic colonies can be seen and these are then stained and counted. 
Only those colonies with fifty or more cells (i.e. those cells which have undergone 
five or more divisions) are counted, since these cells are regarded as having the 
potential to undergo indefinite division. Those cells which have undergone less 
than five divisions are regarded as "dead" in that they have suffered 
radiation-induced loss of reproductive capacity. The traditional mammalian survival 
curve (figure 2) has a "shoulder" at low doses and only becomes exponential at 
higher doses.
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Figure 2 Typical survival curves for mammalian cells exposed to radiation. The fraction of surviving 
cells is plotted on a logarithmic scale against dose on a linear scale. For densely ionizing radiations, 
such as low-energy neutrons, the dose-response curve is a straight line and may be characterized by 
one parameter, the 37°C dose slope or D0. For sparsely ionizing radiations such as x-rays, the dose- 
response curve has an initial shoulder followed by a portion which is straight, or almost straight. The 
curve is characterised by two parameters; the 37% dose slope, D (J, of the straight portion and the 
extrapolation number, n. which is a measure of the "width" of the initial shoulder. Alternatively, the 
width of the shoulder may be specified in terms of the quasithreshold dose, D^, which is the dose at 
which the extrapolated straight portion of the dose-response curve cuts the dose axis.
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This curve is often well fitted by an equation of the form S = 1 - (1 - e 'D/Do) n, 
where S= surviving fraction, D = given dose and Do, n are parameters to be 
estimated (Hall 1988). The extrapolation number (n), where the straight line 
portion of the curve crosses the Y-axis, gives an indication of the size of the 
shoulder and the ability to accumulate and repair sub-lethal damage. Lately, the 
importance of the surviving fraction at 2 Gy (SF2) has emerged. This parameter 
shows the response to therapeutically relevant treatment doses. The literature on 
in vitro sensitivity of human tumours demonstrated a correlation between SF2 and 
the level of clinical response of various tumour types (Fertil and Malaise 1981; 
Deacon et al 1984).
The amount of firm data on the radiobiology of childhood tumours is small and 
differences between cell lines are wide. Data support the view that cells of some 
childhood neoplasms are inherently highly radiosensitive and show a small shoulder 
on the survival curve (Steel and Wheldon 1991). Overall, the data on radiobiology 
of human neuroblastoma cells in vitro indicates moderate radiosensitivity with a low 
capacity for accumulation of sub lethal damage as indicated by the lack of an 
appreciable shoulder on the survival curve (Wheldon et al 1985; Deacon et al 1985; 
Wheldon et al 1986). The use of multiple small fractions of radiation is favoured 
in order to exploit the increased repair capacities of many normal tissues compared 
with neuroblastoma cells (Deacon et al 1985; Wheldon et al 1985). Since 
neuroblastoma grows rapidly both clinically and as a xenograft, short overall 
treatment times are indicated to avoid the problem of repopulation of neoplastic 
cells. Hence accelerated fractionation using small fraction sizes or decreased dose 
rate continuous irradiation would be favoured (Deacon et al 1985; Steel and 
Wheldon 1991).
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TH E GENETICS OF RADIORESISTANCE
The role of oncogenes in conferring radioresistance is controversial and most of the 
work has been done on animal cells. Russell et al were unable to find any 
significant difference between the radiosensistivity of normal mink lung epithelial 
cells and those transfected with either c-myc or H -ras (Russell et al 1992). On the 
other hand, a study of a radiation resistant cell line established from a patient with 
laryngeal cancer which progressed during a course of radiotherapy indicated that 
the transforming gene (in this case abnormal c-raf) could confer the 
radiation-resistant phenotype to recipient cells upon transfection. This same 
activated c-raf could induce tumours in nude mice (Kasid et al 1987). Investigations 
are underway to establish the exact nature of the genetic abnormalities within this 
gene and their effect. It will be important to ascertain whether this activated raf 
gene can enhance DNA repair or stimulate free-radical scavenging (Renan 1990). 
A recent study suggests that oncogenes may increase radioresistance by lengthening 
the time cells spend in G2 phase after irradiation (McKenna et al 1991). Other 
studies have implicated activated ras and c-raf oncogenes in the acquisition of 
tolerance to ionising radiation (Fitzgerald et al 1985; Sklar 1988b; Pirollo et al
1989). However one must view these results with some caution, since a recent study 
on normal rat embryo fibroblasts and a human glioblastoma line indicated that the 
transfection process per se is capable of inducing radioresistance (Pardo et al 1991).
TA RGETED THERAPY
Since advanced stage neuroblastoma is refractory to conventional radiotherapy a 
number of studies have been carried out, both in vitro• and in the clinic, into 
targeted therapy. Monoclonal antibodies bearing radioisotopes (e.g.125I-UJ13A) 
have been utilised, directed against tumour cell surface markers (Allan et al 1983; 
Kemshead et al 1985). Another possible approach to targeting of neuroblastoma 
exploits the expression of nerve growth factor receptor which is widely found in 
these cells (Mairs et al 1991). One agent which has been particularly widely studied
37
is meta-iodobenzylguanidine (mIBG) in which the iodine atom has been replaced 
with the radioisotope 131I (Beierwaltes 1987; Mairs et al 1991). This drug is 
selectively accumulated by catecholamine synthesising cells. mIBG is an analogue 
of the adrenoreceptor neurone blocker guanethidine and is used in many cancer 
centres for localisation, staging and therapy of phaeochromocytoma and 
neuroblastoma. Neuroblastoma cells have biochemical properties which enable 
preferential concentration of catecholamine precursors. Trials have been completed 
on mIBG therapy and one of the main centres for use is Amsterdam. Treatment 
with 131I-mIBG has been brought to the forefront by a particular group who had 
some success with 50 patients who had recurrent disease (Voute et al 1991). Since 
131I is mainly a |3 emitter, the path length is too long to make it an ideal choice for 
treating small micrometastases since most of the radiation is deposited outside the 
cell. Various novel isotopes are being investigated at the moment with shorter 
ranges like 211Astatine incorporated in mABG or 125I. In fact some groups in the 
United States are investigating 125I-mIBG for therapy.
One exciting, though highly speculative, possibility is that of exploiting the high copy 
number of N-myc in a sub-set of neuroblastomas by targeting the gene. This 
involves the use of internucleotide, linkage-protected specific, oligonucleotides 
conjugated to ultra short range Auger emitters such as l23I or 125I. Ideally, normal 
cells, though they accumulate the radiolabelled oligonucleotide, should suffer much 
less DNA damage than tumour cells with amplified N-myc which should (hopefully) 
retain greater amounts of radioactivity.
For the future, new approaches to diagnosis including cytogenetic markers like 
partial monosomy for chromosome 1 and N-myc amplification will play a role in 
improving treatment design. The use of targeted radiotherapy using monoclonal 
antibodies and catecholamine precursors are examples of novel treatments being 
investigated in various world centres presently.
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MATERIALS AND METHODS 
CELL LINES
NB1-G. This cell line was established by monolayer culture of cells released by 
disaggregation of a human tumour xenograft obtained from surgical excision of 
stage 4 abdominal neuroblastoma from a 2 year old male (Carachi et al 1987).
IMR-32. Cell line established from stage 4 abdominal mass in 13 month old male, 
diagnosed as neuroblastoma (Tumilowicz et al 1970).
XRNB1-G. This is a radioresistant sub-line of NB1-G produced by irradiating 
flasks of the parent line once per week at 2 Gy (Russell 1990).
SK-N-SH. This cell line was established from human metastatic neuroblastoma 
tissue (Biedler et al 1973).
SK-N-BE(2)C. Progressive human neuroblastoma obtained from bone marrow 
after therapy with adriamycin, cytoxan and radiation (Reynolds et al 1986).
NB2-G. Cell line from xenograft established from thoracic tumour of male patient 
(Stage 4 neuroblastoma) presenting to Royal Hospital for Sick Children in 1983. 
(Wheldon et al 1985).
NB100. Epidural tumour surrounding spine from a 12 year old female, diagnosed 
as consistent with neuroblastoma (Schlesinger et al 1976).
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MONOLAYER CULTURE
All cell lines were maintained in 75cm2 flasks containing 20mls of Eagle’s Minimum 
Essential Medium with 25mM Hepes buffer, 10% foetal calf serum, 2mM 
glutamine, penicillin/streptomycin (100 IU /m l) and amphotericin B (2.5 jig/ml). 
All media and supplements were obtained from Gibco (Paisley, Scotland). Flasks 
were seeded with 5x10s cells, and kept in an atmosphere of 5% C 0 2 at 37°C.
SPHEROID CULTURE
Multicellular tumour spheroids were produced by continuous stirring of 
approximately 2xl06 cells in Techne (Cambridge, U.K.) stirrer vessels for 3-4 days 
at 37°C, 5% C 0 2. Spheroids of about 300 pm diameter were assayed for response 
to radiotherapy or chemotherapy. Multicellular tumour spheroids are often 
employed as in vitro models for human tumour studies. These have a number of 
distinctive features which make them ideal for this, including heterogeneity of 
metabolism and cell kinetics as the spheroid size increases, and availability of a 
number of end points. Spheroids may be an especially good model for avascular 
micro-metastases in vivo and it may be in the context of adjuvant therapy that in 
vitro spheroid studies may be of the greatest relevance (West et al 1980; 
Mueller-Klieser 1987).
IRRADIATION PROCEDURE
Spheroids were transferred to 25 cm2 flasks and each flask was irradiated on a ^Co 
unit with doses from 0.5 - 5 Gy, using a 0.8 cm perspex ‘build-up’ to ensure 
maximum energy deposition. The dose rate was approximately 1 Gy per minute.
Several pilot studies were performed on each cell line to assess the plating 
efficiency and to ascertain the amount of radiation required to produce a 
reasonable (1 log) cell kill before deciding on the range of radiation to use. For 
example, the NB1-G line required approximately 2.5 Gy to produce 1 log cell kill. 
Therefore the upper limit was set at 3.5 Gy. The SK-N-BE(2)C cell line needed 
4 Gy for the same effect. Therefore the upper limit was set at 5 Gy.
CHEM OTHERAPY
Spheroids were transferred to universal containers, medium was removed and the 
spheroids were resuspended in cisplatin (Cyanamid, U.K.) ranging in concentration 
from 2.5 \iM - 20 pM. These were incubated at 37°C for 1 hour and the drug was 
removed by washing three times in Earle’s balanced salt solution. Once again, 
several pilot experiments were done on each cell line to set a range of doses of 
cisplatin, as was done for radiation.
Two end points could now be pursued to estimate response to radiation and 
chemotherapy. These were either spheroid regrowth or colony formation following 
spheroid dissagregation.
SPHEROID REGROW TH
After treatment spheroids were sorted into agar coated wells of 24 well multiwell 
plates using one plate for each dose of radiation or chemotherapy. The plates were 
placed in a 5% C 0 2 incubator at 37°C. The cross-sectional area of the spheroids 
was measured twice per week using an image analysis system (Twentyman 1982) 
and 0.5 mis medium was added to the wells once per week. Measurements were 
stopped when more than 50% of the spheroids in the plate had reached 
approximately 1mm in diameter. Once the spheroids reach this size their growth 
rate begins to plateau and the middle of the spheroid becomes necrotic. For each 
treatment group, plots can be made of median log10 volume against day of 
measurement to produce spheroid growth curves. Only those experimental groups 
where more than 50% of the spheroids regrew were used to produce growth curves. 
Three separate experiments were carried out for each cell line.
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ESTIMATION OF CELL SURVIVAL FROM SPHEROID REGROWTH 
Regrowth plots for treated spheroids initially show a decrease in the rate of growth 
which eventually becomes parallel to the control plot (see Fig. 3). If it is assumed 
that treatment has little effect on growth kinetics of the surviving cells, then by back 
extrapolation of the regrowth curves to zero time, an estimation can be made of 
median cell survival (Wheldon et al 1985). Using the equation S = No’/No where 
S = survival, No’ = median log10 (volume) of treated spheroids on day zero and No 
= median logl0 (volume) of control spheroids on day zero.
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F ig u re  3. Estim ation of cell survival from  spheroid regrow th. 
Plot of median log volume versus time. This illustrates how the 
survival of treated spheroids was estim ated by back-extrapolation 
o f the treated growth curve to zero time.
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ESTIMATION OF CELL SURVIVAL FROM  COLONY FORMATION.
After treatment spheroids were disaggregated using a series of needles. Samples 
were examined microscopically to ensure a single cell suspension had been 
achieved. Cells were then plated out into 25cm2 flasks at various concentrations, 
using three flasks per treatment group. Some cell lines (e.g. NB1-G and 
XRNB1-G) required feeder layers. These were produced by heavily irradiating a 
cell suspension at 50 Gy and placing 106 of these cells into each experimental flask. 
The flasks were then incubated at 37°C, 5% C 0 2 for about 10-14 days until 
macroscopic colonies could be seen. These were then stained with Carbol Fuschin 
(10% in water) and counted. Survival curves were produced from the results of at 
least three separate experiments. In each experiment, the mean of three surviving 
fractions was determined per dose. The multitarget (page 35) model was used to 
fit the curves.
ESTIMATION OF N-myc COPY NUMBER
DNA was extracted from cell lines using Proteinase K followed by 
phenol/chloroform extraction (Bimie and Graham 1985). DNA was digested with 
E coR l, and samples were electrophoresed through 0.8% (w/v) agarose gels (using 
X /  Hind III fragments (Gibco, UK) as molecular weight markers) and blotted 
(Southern 1975) onto nylon filters (Amersham). These were simultaneously 
hybridised to radioactve p-Nbl probe (1 kbp E coR l/B am H l insert of pBR322) 
(Schwab et al 1983; Kohl et al 1983) and the 5’end of the M-bcr probe (Bartram 
et al 1986). Probes were labelled with 32P deoxy-cytidine triphosphate using the 
random primer method. The specific activity of the probes was approximately 2xl07 
counts per minute per pg of probe. The second probe was used to check the 
amount of DNA loaded into each well. N-myc copy number was assigned by 
densitometry of autoradiographs (Sun, U.K.). Placental DNA, which has 
unamplified N-myc was used as single copy control. Several preliminary 
autoradiographs were produced using serial dilutions of each cell line DNA to test
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the accuracy of the densitometer and to decide how much DNA to load in each 
well. Then, autoradiographs containing representative signals for each cell line 
were scanned, and the N-myc copy number calculated. To set up the densitometer, 
a standard picture was first scanned to calibrate the instrument. Then, the 
autoradiograph of interest was read and an output of the optical density in each 
lane was produced, with any background subtracted. The copy number was then 
calculated for each cell line by comparison of optical density readings with single 
copy placental DNA.
ESTIMATION OF N-myc EXPRESSION
Total RNA was extracted from cell lines using the RNAzol B kit, (Biogenesis Ltd., 
England) and the integrity of the RNA was assessed by electrophoresing on a 0.8% 
(w/v) agarose gel. Hela cells were used as a negative control since they do not 
express N-myc (Nisen et al 1988). Total RNA was electrophoresed in a 1% 
agarose/formaldehyde (w/v) gel, with 10 pg of sample loaded into each lane (Davis 
et al 1986). The two major sub-units of ribosomal RNA (28S and 18S) were used 
as internal markers. By Northern blotting and subsequent hybridisation to 
radiolabelled p-Nbl (as above), a signal was seen at 3 kb which corresponds to the 
size of N-myc messenger RNA. The level of expression in cell lines was compared 
by "dot-blot" analysis (Sambrook et al 1989). An expression value of 1 was assigned 
to SK-N-SH (Kohl et al 1984) and a value of 10 to XRNB1-G (which gave the 
strongest signal). All other cell lines were compared to these. Again, preliminary 
autoradiographs with serial dilutions of RNA were scanned before arriving at the 
final results.
STATISTICAL ANALYSIS
Statistical analysis was undertaken following the advice of Dr. T.E. W heldon and 
Dr. J. Paul (Clinical Trials Office, Beatson Oncology Centre, W estern Infirmary). 
Analysis was carried out to evaluate the possible correlation of N-myc copy number
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or N-myc expression to SF2 or cisplatin isodose (the dose of cisplatin required to 
produce 1 log cell kill), and also of N-myc copy number to N-myc expression. Data 
analysis was first done using the Spearman’s rank correlation test to assess 
correlation without assuming linearity. Where a positive indication of correlation 
was found, least-squares analysis was undertaken to further elucidate the nature of 
the relationship. This analysis was carried out using the "statworks" and 
"cricketgraph" programs on an Applemacintosh LC computer.
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N-myc COPY NUMBER
N-myc amplification as assessed by laser densitometry showed a range of copy 
numbers (tables 2 & 3; figs. 4 & 5). The cell lines SK-N-SH and NB100 had 
unamplified N-myc. IMR-32, NB1-G, XRNB1-G and NB2-G had copy numbers 
20, 25, 25 and 30 respectively. SK-N-BE(2)C had the unusually high copy 
number of 800. Human placental DNA was used as single copy control.
N-myc EXPRESSION
Northern blot examination of RNA isolated from neuroblastoma cell lines 
showed that the labelled p-NBl probe hybridised to a 3 kb mRNA (fig. 6). The 
level of expression, tested by "dot blot" analysis, showed cell lines SK-N-SH and 
NB100 to be expressing at base-line levels, with the strongest signal being shown 
by XRNB1-G (fig. 7). By arbitrarily assigning a value of 10 to the degree of 
expression in XRNB1-G, the expression levels of other cell lines were as shown 
in tables 2 & 3.
RADIOSENSITIVITY
The survival curves (figs. 8-14) were constructed as described previously. 
Radiosensitivity was assessed by the surviving fraction at 2 Gy (SF2). This was 
estimated by drawing a line from 2 Gy on the x-axis onto the curve and then 
extending this line horizontally onto the y-axis (see figure 8 ). This param eter 
is of clinical relevance as this is a typical fractionated dose. SF2 values of the 
cell lines assayed ranged from 0.13 to 0.52 (table 2).
CHEMOSENSITIVITY
Response to chemotherapy was estimated by comparison of isoeffective dose: 
the concentration ( pM) of cisplatin required to produce one log cell kill. This 
was estimated by drawing a line from -1 on the y-axis onto the survival curve 
and extending this line vertically onto the x-axis (see figure 15). Isoeffective 
doses ranged from 7.5 pM for NB1-G to 13 pM for SK-N-BE(2)C (table 3). 
Survival curves (figs. 15-21) show that NB1-G and NB100 lack shoulders 
indicating that these cell lines are more sensitive to low doses of cisplatin than 
the others.
Cell line N-myc copy no N-myc expression sf2
SK-N-SH 1 1 0.13
NB100 1 1 0.44
IMR-32 20 3 0.25
NB1-G 25 7 0.17
XRNB1-G 25 10 0.23
NB2-G 30 3 0.24
SK-N-BE(2)C 800 2 0.52
Table 2 Comparison of N-myc copy number, level of N-myc 
expression and SF2 values for the seven cell lines.
Cell Line N-mvc copy N-mvc Iso effectiv e
num ber expression dose of
cisplatin! uM)
SK-N-SH 1 1 7.5
NB100 1 1 8.5
IMR-32 20 3 10
NB1-G 25 7 7.5
XRNB1-G 25 10 11
NB2-G 30 3 11
SK-N-BE(2)C 800 2 13
Table 3 Comparison of N-myc copy number, level of N-myc 
expression and isoeffective dose of cisplatin (^M) for the seven 
cell lines.
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Figure 4a. S outhern  b lo t analysis of N -m yc copy  
num ber. DNA was digested with EcoRl, e lectrophoresed  
on 0.8% (w/v) agarose gels, an d  analysed  by S ou thern  
b lo t. Each well con ta ined  3^g of DNA except SK-N- 
BE(2)C (50ng) and  the single copy N-myc line NB100 
(20^g). Placental DNA (20 n-g) was used  as single copy 
control.
After electrophoresis, the DNA was transferred  to ny lon  
m em b ran e  an d  h y b rid ised  s im u ltan eo u sly  to 3 2p. 
lab e lled  p-N bl and  5’ bcr p robes. Specific ac tiv ity  
of these was approxim ately 2 x l0 7 c.p.m./^ig. The p -N bl 
p robe bound to a 2kbp fragm ent.
Figure 4b . The bcr p robe  (used  to verify  load ing) 
bound  to a 13kbp fragment.
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Figure 5. Southern  blot analysis of N-myc copy num ber. DNA was 
d igested  w ith EcoRl, electrophoresed  on 0.8% (w/v) agarose gels, 
an d  analysed  by Southern blot. Wells contain 20|xg of p lacental and  
SKNSH DNA and  3(mg of NB2-G DNA. After electrophoresis, DNA was 
tran sfe rred  to nylon  m em brane an d  hybrid ised  sim ultaneously  to 
32p-iabelled p-N bl and  5’ bcr probes. Specific activity of these was 
approxim ately  2x107 c.p.m./Vg. The p-N bl p robe bound  to a 2kbp 
fragm ent, an d  the bcr p robe (used to verify loading) b o u n d  to a 
13 kbp fragm ent.
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Figure 6. N o rth e rn  b l o t  
analysis of N -m yc ex p ress io n . 
Total RNA was e lec tro p h o resed  
on fo rm aldehyde/agarose  gels, 
and  analysed by  N orthern  blot. 
A fter t r a n s fe r r in g  to  n y lo n  
m e m b ra n e , th e  b lo t  w as 
h y b r id is e d  to 32P - la b e l l e d  
p -N b l p ro b e  w ith  a specific 
activ ity  of ap p ro x im ate ly  2 x 
107 cpm per ^g.
Each well c o n ta in e d  10f.ig of 
total RNA.
Figure 7. Dot b lo t  
analysis of N -m y c  
expression. 2 .5 ^  of 
to ta l  RNA w a s  
“d o tted ” onto  ny lon  
f i l t e r  a n d  
h y b r i d i s e d  a  s 
above . H ela ce lls  
w ere  u se d  as a 
n e g a tiv e  c o n t r o l  
since th e y  do  n o t  
e x p re s s  N - m y c  
RNA.
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Figure 8. Survival curve for cell line SK-N- 
BE(2)C shows logio (surviving fraction) versus 
dose o f ra d ia tio n  (Gy). S p h ero id s  w ere 
irrad ia ted  on a 60Co source, d isaggregated  to 
form  a single cell suspension, an d  p la ted  to 
fo rm  co lon ies. S u rv iv a l c u rv e s  w ere  
constructed  from  the  resu lts of a t least th ree  
separa te  experim ents. In each  experim ent, 
the  m ean  of th ree  surviv ing  frac tio n s was 
determ ined per dose.
The broken  line on  the p lo t illu stra te s  how  
the  surv iv ing  fra c tio n  a t 2Gy (SF2 ) was 
derived.
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Figure 9. Survival curve fo r cell line SK-N- 
SH shows logio (surv iv ing  frac tio n ) v ersu s  
dose of ra d ia tio n  (Gy). S p h ero id s  w ere 
irrad ia ted  on a 60Co source, d isaggregated  to 
form  a single cell suspension, an d  p la ted  to 
fo rm  co lonies. S u rv iv a l c u rv e s  w ere  
constructed from  the results of a t least th ree  
separate  experim ents. In each  experim en t, 
the m ean of th ree  surv iv ing  frac tio n s  was 
determ ined per dose.
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Figure 10. Survival curve for cell line NB100 
shows logio (surviving fraction) versus dose 
of rad ia tion  (Gy). Spheroids were irrad ia ted  
on a  60Co source, d isaggregated  to fo rm  a 
single cell suspension , an d  p la ted  to  fo rm  
colonies. Survival curves w ere c o n s tru c te d  
from  the resu lts o f a t least th re e  se p a ra te  
experim ents. In each experim ent, th e  m ean  
of th ree  surviving fractions was d e te rm in ed  
per dose.
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Figure 11. Survival curve for cell line NB2-G 
shows logio (surviving fraction) versus dose 
of rad ia tion  (Gy). Spheroids w ere irra d ia ted  
on a 6 0 C o  source, d isaggregated  to fo rm  a 
single cell suspension , an d  p la ted  to fo rm  
colonies. Survival curves w ere c o n s tru c te d  
from  the resu lts of a t least th re e  se p a ra te  
experim ents. In each experim ent, the  m ean  
of th ree  surviving fractions was d e te rm in ed  
per dose.
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Figure 12. Survival curve for cell line IMR- 
32 shows logio (surviving frac tion ) v ersu s  
dose of ra d ia tio n  (Gy). S ph ero id s w ere 
irrad ia ted  on a 60Co source, d isaggregated  to 
form  a single cell suspension, an d  p la ted  to  
fo rm  co lon ies. S u rv iv a l c u rv e s  w e re  
constructed  from  the results of a t least th ree  
separate  experim ents. In each  experim en t, 
the m ean of th ree  surv iv ing frac tio n s was 
determ ined per dose.
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Figure 13. Survival curve fo r cell line NB1-G 
shows logio (surviving fraction) versus dose  
of rad ia tion  (Gy). Spheroids w ere ir ra d ia te d  
on a 60Co source, d isaggregated  to fo rm  a 
single cell suspension, an d  p la ted  to  fo rm  
colonies. Survival curves w ere c o n s tru c te d  
from  the resu lts of a t least th re e  se p a ra te  
experim ents. In each experim ent, th e  m ean  
of th ree  surviving fractions was d e te rm in ed  
per dose.
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F igu re 1 4 . Survival cu rv e  fo r  cell lin e  
XRNBI-G shows log io  (su rv iv ing  frac tio n ) 
versus dose of rad ia tion  (Gy). Spheroids were 
irrad ia ted  on a 60Co source, d isaggregated  to 
form  a single cell suspension, an d  p la ted  to  
fo rm  co lon ies. S u rv iv a l c u rv e s  w ere  
constructed  from  the resu lts of a t least th ree  
separa te  experim ents. In each  experim ent, 
the m ean of th ree  surv iv ing  frac tio n s  was 
determ ined per dose.
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Figure 15. Survival curve fo r cell line NB100 
shows log io  (surviving fraction) versus dose 
of cisplatin (^M). Spheroids w ere incubated  
w ith cisplatin, w ashed th ree  tim es in  Earles 
balanced salt solution, disaggregated to form  a 
single cell suspension, an d  p la ted  to  fo rm  
colonies. Survival curves w ere c o n s tru c te d  
from  the resu lts of a t least th re e  se p a ra te  
experim ents. In each experim ent, the  m ean  
of th ree  surviving fractions was d e te rm in ed  
per dose.
The broken  line on the p lo t illu stra te s  how  
the isoeffective dose of cisplatin  was derived , 
i.e. the dose required to produce 1 log cell kill.
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Figure 16. Survival curve for cell line NB1-G 
shows logio (surviving fraction) versus dose 
of cisplatin (inM). Spheroids were incubated  
w ith cisplatin, w ashed th ree  tim es in  Earles 
balanced salt solution, disaggregated to form  a 
single cell suspension, an d  p la ted  to fo rm  
colonies. Survival curves w ere c o n s tru c te d  
from  the results of a t least th ree  se p a ra te  
experim ents. In each experim ent, the  m ean  
of th ree surviving fractions was d e te rm in ed  
per dose.
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Figure 17. Survival curve for cell line SK-N- 
SH shows logio (surviving frac tion ) versus 
dose of c isp latin  (^M). S p h ero id s  w ere 
incubated  with cisplatin, w ashed th ree  tim es 
in Earles balanced salt solution, disaggregated 
to form  a single cell suspension, and  p la ted  to 
fo rm  colon ies. S u rv iv a l c u rv e s  w ere  
constructed  from  the results of a t least th ree 
separa te  experim ents. In each experim ent, 
the m ean of th ree  surv iv ing frac tio n s was 
determ ined per dose.
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Figure 18. Survival curve for cell line IMR- 
32 shows logio (surviving frac tion ) versus 
dose of c isp latin  (nM). S p h ero id s w ere 
incubated  with cisplatin, w ashed th ree  tim es 
in Earles balanced salt solution, disaggregated 
to form  a single cell suspension, and  p la ted  to 
fo rm  colonies. S u rv iv a l c u rv e s  w ere  
constructed from  the results of a t least th ree  
separate  experim ents. In each experim ent, 
the m ean of th ree  surviving frac tio n s  was 
determ ined ner dose.
NB2-G
0
LOG ( S F )
DOSE (juM)
0 5 10 15 20
. 00
1 . 0 0 -
l .5 0 -
Figure 19. Survival curve for cell line NB2-G 
shows logio  (surviving fraction) versus dose 
of cisplatin (jiM). Spheroids w ere incubated  
w ith cisplatin, w ashed th ree  tim es in  Earles 
balanced salt solution, disaggregated to form  a 
single cell suspension, an d  p la ted  to  fo rm  
colonies. Survival curves w ere c o n s tru c te d  
from  the results of a t least th re e  se p a ra te  
experim ents. In each experim ent, the  m ean  
of th ree  surviving fractions was d e te rm in ed  
per dose.
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Figure 20. Survival curve for cell line SK-N- 
BE(2)C shows logio (surviving fraction) versus 
dose of c isp la tin  (iiM). S p h ero id s  w ere  
incubated  with cisplatin, w ashed th ree  tim es 
in Earles balanced salt solution, d isaggregated 
to form  a single cell suspension, and  p la ted  to 
fo rm  co lonies. S u rv iv a l c u rv e s  w ere  
constructed  from  the results of a t least th ree  
separa te  experim ents. In each  experim en t, 
the  m ean of th ree  surviving frac tio n s was 
determ ined per dose.
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F igu re 2 1 . Survival cu rve  fo r cell lin e  
XRNBI-G shows lo g io  (surviving f ra c tio n )  
versus dose of cisp latin  (jxM). S p h ero id s 
were incubated  w ith cisplatin, w ashed th ree  
tim es in  Earles b a lan ce d  sa lt so lu t io n , 
disaggregated to form  a single cell suspension, 
and  p lated  to form  colonies. Survival curves 
were constructed  from  the resu lts of a t least 
th re e  se p a ra te  ex p e rim e n ts . In e a c h  
experim ent, the  m ean  of th re e  su rv iv in g  
fractions was determ ined per dose.
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RELATIONSHIP BETWEEN N-myc COPY NUMBER AND SF2 
The relationship between SF2 and the log10 (N-myc copy number) is shown in 
figure 22. A logarithmic scale was used in order to accomodate the high copy 
number of 800. Spearman’s rank correlation test (see materials and methods) 
was applied in order to evaluate the significance of association. Spearman’s 
statistic = 0.327; p = 0.474. This shows no significant relation between the 
two, therefore no further statistical analysis was done.
RELATIONSHIP BETWEEN N-myc EXPRESSION AND SF2 
Figure 23 shows the relationship between SF2 and N-myc expression for the cell 
lines. Spearman’s rank correlation test gave the following results: Spearman’s 
statistic = -0.255; p = 0.582. This shows no significant relationship between the 
two and, therefore, no further statistical analysis was done.
RELATIONSHIP BETWEEN N-myc COPY NUMBER AND ISOEFFECTIVE DOSE 
OF CISPLATIN
The relationship between log10 (N-myc copy number) and isoeffective dose of 
cisplatin indicated the following: Spearman’s statistic = 0.750; p = 0.052. This 
indicates borderline significance, therefore a least squares fit analysis was done 
to investigate the relationship between N-myc copy number and isoeffective 
dose. This showed R = 0.708; p = 0.05. The relationship between isoeffective 
dose and the log of N-myc copy number (fig. 24) gave an R value (least squares 
analysis) = 0.806; 0.01 < p < 0.05. These results indicate a possible relation 
between isoeffective dose and N-myc copy number. Therefore, the relationship 
could be of approximate linearity between isoeffective dose and log N-myc copy 
number.
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Figure 22. R ela tio n sh ip  b e tw een  N -m y c  
copy n u m b er a n d  SF2 . Plot of su rv iv ing  
fraction at 2Gy (SF2) versus log 10 (N-myc copy 
num ber) fo r seven cell lines. Each p o in t 
re p re se n ts  th e  re s u lt  of a t  le a s t th re e  
separate experim ents for each cell line. SF2 
values were derived  from  rad ia tio n  survival 
curves.
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Figure 23 . Relationship betw een N -m yc 
expression and SF2 . Plot of surviving fraction 
at 2Gy (SF2) versus level of N-myc expression 
for seven cell lines. Each point represents the 
result of at least three separate experim ents 
for each cell line. SF2 values were derived  
from radiation survival curves.
Log i o  (N-myc copy no)
F ig u re  24 . R e la tio n sh ip  b e tw een  N -m y c  
copy  n u m b e r  a n d  iso e ffec tiv e  d o se  o f 
cisplatin. Plot of isoeffective dose (pM dose 
required  to produce 1 log cell kill) of cisplatin  
versus logio  (N-myc copy num ber) for seven 
cell lines. Each po in t rep resen ts  the  re su lt of 
a t least th ree  separate  experim ents fo r each  
cell line. Isoeffective dose was deriv ed  from  
survival curves.
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N-myc EXPRESSION
F ig u re  25 . R e la tio n sh ip  b e tw e en  N -m y c  
expression and  isoeffective dose of cisplatin . 
Plot of isoeffective dose ( i^M dose req u ired  to 
p roduce  1 log cell kill) of c isp la tin  versus 
level of N-myc expression in seven cell lines. 
Each p o in t rep resen ts  the re su lt of a t least 
th ree  separate experim ents for each cell line. 
Isoeffective dose was deriv ed  from  survival 
curves.
EXPRESSION
Log 10 (N-myc copy no)
Figure 26. Relationship betw een N-m yc 
expression and N-myc copy number. Plot of 
the level of N-myc expression versus logio 
(N-myc copy number) for seven cell lines. 
The point on the Y axis represents two co­
incident points.
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RELATIONSHIP BETWEEN N-myc EXPRESSION AND ISOEFFECTIVE 
DOSE OF CISPLATIN
Figure 25 shows the relationship between isoeffective dose of cisplatin and 
N-myc expression. Spearman’s rank correlation gave Spearman’s statistic = 
0.222; p = 0.632. This shows no significant correlation between the two 
therefore, no further statistical analysis was done.
RELATIONSHIP BETWEEN N-myc EXPRESSION AND N-myc COPY 
NUMBER
Figure 26 shows the relationship between N-myc expression and log10 (N-myc 
copy number). Spearman’s rank correlation test showed the following: 
Spearman’s statistic = 0.463; p = 0.295. This indicated no significant relation 
between the two and, therefore, no further statistical analysis was carried out.
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DISCUSSION
D ata for radiation survival curves show a range of SF2 values from 0.13 to 0.52 
(table 2). From published data, an average value for the SF2 of neuroblastoma 
cell lines is approximately 0.2, whereas the relatively radioresistant melanomas, 
osteosarcomas and glioblastomas average 0.5 (Deacon et al 1984; Steel and 
W heldon 1990). Therefore, NB100 and SK-N-BE(2)C, which have SF2 values 
of 0.44 and 0.52 respectively (table 2) indicate unusually high radioresistance for 
neuroblastomas. These two cell lines have n values of 5 and 3 respectively, 
indicating a shoulder on the initial portion of the survival curve and some ability 
to repair sub-lethal damage. This contrasts with NB1-G which has an n value 
of 1.
Table 4 indicates the N-myc copy number found for cell lines in this study, 
compared to the available information from other studies: -
Cell Line This Study Others
IMR-32 20 15-20 Schwab et al 1983 
25 Kohl et al 1983
SKNSH 1 1 Kohl et al 1983 
1 Schwab et al 1983
NB100 1 1 Kohl et al 1983
NB1-G 25 20-30 Carachi et al 1987
SK-N-BE(2)C 800 -
SK-N-BE(2) - 170 Rosen et al 1986
Table 4 Comparison of N-myc copy numbers found in this study with the 
available published data.
Tables 2 and 3 show that the level of expression is not necessarily reflected in 
the degree of amplification of N-myc. This has been shown by others as 
mentioned previously on page 23. It would appear that N-myc expression is not 
a good prognostic indicator.
These studies have demonstrated that neither N-myc amplification nor its 
expression bears a strong relationship to the survival of cultured human 
neuroblastoma cells following their treatment with ionising radiation. Cisplatin 
studies showed no relation between N-myc expression and response to treatment. 
However, there may be a correlation between N-myc copy number and cisplatin 
resistance. This represents the first demonstration of a possible explanation for 
treatment failure in neuroblastoma patients with amplified N-myc. W hether this 
is due to N-myc enhanced DNA repair following cisplatin-induced cross-link 
damage or due to decreased cisplatin uptake remains to be investigated. In 
particular, the relationship between isoeffective dose of cisplatin and the 
logarithm of N-myc copy number showed a significant correlation. This would 
suggest that beyond a certain threshold value for N-myc copy number, prognosis 
is not reflected by degree of amplification. For example, a cell line with 800 
copies of N-myc would not be ten times more chemoresistant than one with 80 
copies.
There have been very few investigations into N-myc copy number and expression 
before and after chemotherapy in neuroblastoma patients. Those studies which 
have been carried out indicate an increase in N-myc expression after treatment, 
but no consistency in alteration of N-myc copy number (Rosen et al 1986; Tonini 
et al 1987; Kuroda et al 1991). These were not extensive studies and only 
involved a few patient samples. Until larger studies of this type has been carried 
out, the relationship between N-myc gene and drug resistance will remain 
unclear.
Investigations into the N-myc protein have shown it to be 62-64 kd in size and 
located in the nuclear fraction of human neuroblastoma cells (Igekaki et al 1986) 
Immunohistochemical techniques can be used to stain for the protein, and a
correlation has been found between positive staining and a poor prognosis 
(Hashimoto et al 1989). As with the c-myc protein, the N-myc gene product 
appears to bind to DNA and, along with other members of the myc family, 
appears to function in the control of cellular proliferation. It is possible that the 
N-myc protein interferes with the interaction between cisplatin and DNA, 
thereby reducing its cytotoxicity. Alternatively N-myc protein may enhance DNA 
repair following cisplatin-induced cross-link damage. Although the function of 
the N-myc protein is unknown in either neoplastic or normal tissues, it has been 
suggested that it may regulate gene expression during embryonic development 
since myc proteins have been observed to contain two structural domains 
previously seen in transcription factors (Collum and Alt 1990; Nakajiama et al 
1989). Rosolen et al (1990) used synthetic anti-sense oligonucleotides to 
specifically inhibit N-myc m-RNA without affecting c-myc and showed a resulting 
decrease in growth in the CHP100 cell line (neuroepithelioma: single copy 
N -myc).
As discussed earlier (page 25) amplified N-myc may constitute as little as 0.1% 
of an HSR; therefore there may be other important genes residing here. It is 
possible that cisplatin resistance could be the result of expression of unknown 
genes which are co-amplified with N-myc. Since N-myc over-expression per se 
in single copy tumours does not seem to be associated with a poor outcome the 
question has been raised as to whether or not N-myc is the critical gene 
expressed from the amplified domain in tumours with N-myc amplification 
(Brodeur 1990). Indeed, it is possible that N-myc is a marker for another gene 
or genes which are responsible for poor prognosis (Brodeur 1990).
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CONCLUSION AND IDEAS FOR THE FUTURE
The purpose of this study was to investigate the relationship between N-myc 
amplification/expression and resistance to radiotherapy and cisplatin in 
neuroblastoma cell lines. The results suggest that there may be a relationship 
between N-myc copy number and resistance to cisplatin. This could have 
important clinical relevance since cisplatin, in combination with other drugs, is 
one of the main treatments used to cure patients with neuroblastoma. Despite 
the fact that no correlation was found between copy number and resistance to 
radiotherapy, there is no doubt that N-myc copy number is a good prognostic 
indicator. For the future, there may be a number of issues worth investigating. 
For example, this study only looked into cisplatin sensitivity whereas a number 
of drugs could be used, e.g. vincristine or cyclophosphamide. It would be 
worthwhile exploring whether N-myc amplification confers resistance to these 
drugs. It would also be of interest to study a cell line with a hundred or so 
copies of N-myc. Lately, the importance of chromosome lp  deletion has 
emerged and this may be a candidate for a tumour suppressor gene (see page 
19) or the site of a possible predisposition gene. In those patients with N-myc 
amplification, perhaps extra copies of N-myc are somehow increasing the 
turnover rate of the tumour cells. The antibody Ki67, which binds to an epitope 
uniquely expressed in dividing cells, may be a useful tool, for in vivo studies of 
the growth of patients’ tumours. N-myc amplification may be enhancing 
metastatic spread, and it may be worthwhile carrying out an investigation to test 
this hypothesis.
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